Publicaciones

Selección de publicaciones científicas mas relevantes

    1. New England Journal of Medicine. 2010; 362(14): 1348-1350.
    2. Diabetes Care. 2010, 33(2): 290-293.
    3. Molecular Endocrinology, 2009; 23(12):1983–1989
    4. Diabetes. 2004; 53(8):2164-8.
    5. Diabetes. 2002;51(4):1240-6.
    6. New England Journal of Medicine, 2001; 344 (21): 1588-1592.
    7. Diabetología, 2001; 44: 898-905.
    8. Diabetología; 1999. 42:1175-1186.
    9. Diabetes. 1999. 48:1698-1705.
    10. New England Journal of Medicine. 1998. 22; 338(4): 226-30.

PUBLICACIONES CIENTIFICAS

  1. Luis Miguel Álvarez-Aragón, Antonio Luis Cuesta-Muñoz, Inmaculada Álvarez-López. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality. Clin Infect Dis. 2020 Apr 8: ciaa402.
  2. Francisca Beatriz Rivas-Sánchez, Estíbaliz Romero-Masa, María Rocío Pacheco-Yepes, Antonio Luis Cuesta-Muñoz, Ricardo Gómez- Huelgas. Diabetes rápidamente progresiva como primera manifestación de un adenocarcinoma de páncreas. Rev Esp Casos Clin Med Intern (RECCMI). 2017 (Ago); 2(2): 68-70
  3. Gavito AL, Bautista D, Suarez J, Badran S, Arco R, Pavón FJ, Serrano A, Rivera P1, Decara J, Cuesta AL, Rodríguez-de-Fonseca F, Baixeras E. Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice. PLoS One. 2016; 22; 11(6).
  4. Gavito AL, Cabello R, Suarez J, Serrano A, Pavón FJ, Vida M, Romero M, Pardo V, Bautista D, Arrabal S, Decara J, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Br J Pharmacol. 2016; 173(6):1070-84.
  5. Gomez-Huelgas R, Narankiewicz D, Villalobos A, Wärnberg J, Mancera-Romero J, Cuesta AL, Tinahones FJ, Bernal-Lopez MR. Prevalence of Metabolically Discordant Phenotypes in a Mediterranean Population. The Imap Study. Endocr Pract. 11:1-33. 2013.
  6. Vida M, Serrano A, Romero-Cuevas M, Pavón FJ, González-Rodriguez A, Gavito AL, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E.IL-6 cooperates with peroxisome proliferator-activated receptor-α-ligands to induce liver fatty acid binding protein (LFABP) up-regulation. Liver Int. 33(7):1019-28. 2013
  7. Bernal-Lopez MR, Santamaría-Fernandez S, Lopez-Carmona D, Tinahones FJ, Mancera-Romero J, Peña-Jimenez D, Jansen-Chaparro S, Baca-Osorio AJ, Cuesta-Muñoz AL, Serrano-Rios M, Gomez-Huelgas R. A1C in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice. Diabetic Medicine. 2011; 28(11):1319-22.
  8. Sameer Kassem, Sonal Bhandari, Pablo Rodríguez-Bada, Nadia Cobo-Vuilleumier, Roja Motaghedi, Maayan Heyman, M. Adelaida García- Gimeno, Pascual Sanz, Noel K. Maclaren, Jacques Rahier, Benjamin Glaser, and Antonio Luis Cuesta-Muñoz. Large Islets, Beta-Cell Proliferation, Hypoglycemia and a Glucokinase Mutation.  New England Journal of Medicine. 2010; 362(14): 1348-1350.
  9. Cuesta-Muñoz AL, Tuomi T, Cobo-Vuilleumier N, Koskela H, Odili S, Stride A, Buettger C, Otonkoski T, Froguel P, Grimsby J, Garcia-Gimeno M, Matschinsky FM. Clinical Heterogeneity in Monogenic Diabetes Caused by Mutations in the Glucokinase Gene (GCK-MODY). Diabetes Care. 2010, 33(2): 290-293.
  10. Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, Rodriguez-Bada P, Colombo C, Lenzi L, Garcia-Gimeno MA, Bermudez-Silva FJ, Rodriguez de Fonseca F, Banin P, Aledo JC, Baixeras E, Sanz P, Cuesta-Muñoz AL. Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Molecular Endocrinology, 2009; 23(12):1983–1989
  11. Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodríguez-Bada P, García-Gimeno MA, Baixeras E, Weber J, Olek K, Sanz P, Mayatepek E,Cuesta-Muñoz AL. Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res., 2009; 41(4):320-6.
  12. Aledo JC, Jiménez-Rivérez S, Cuesta-Munoz A, Romero JM. The role of metabolic memory in the ATP paradox and energy homeostasis. FEBS J. 2008; 275(21):5332-42.
  13. Cahuana GM, Tejedo JR, Hmadcha A, Ramírez R, Cuesta AL, Soria B, Martin F, Bedoya FJ.. Nitric oxide mediates the survival action of igf-1 and insulin in pancreatic β-cells. Cell Signalling. 2008; 20(2):301-310
  14. F.J. Bermúdez-Silva, J. Suárez, E. Baixeras, N. Cobo, D. Bautista, A.L. Cuesta-Muñoz, E. Fuentes, P. Juan-Pico, M.J. Castro, G. Milman, R. Mechoulam, A. Nadal and F. Rodríguez de Fonseca. Presence of functional cannabinoid receptors in human endocrine pancreas.  Diabetologia. 2008; 51(3): 476-487
  15. Antonio L. Cuesta Muñoz and  Nadia Cobo Vuilleumier. Hiperinsulinismo Monogénico. Avances en Diabetología. 2007; 23(5): 350-357
  16. Montero F, Baglietto-Vargas D, Moreno-González I, López-Tellez JF, Cuesta-Munoz AL, Gutiérrez A, Aledo LC. Glutaminase activity is confined to the mantle of the islets of Langerhans. Biochimie. 2007; 89:1366-1371
  17. A L. Cuesta-Munoz.Diabetes Monogénicas.En Tratado SED de Diabetes Mellitus. Bases moleculares, clínicas y tratamiento. 2007; Pag 47. Editorial Médica Panamericana.
  18. Briones RM, Miranda JM, Mellado-Gil JM, Castro MJ, Gonzalez-Molina M, Cuesta-Muñoz AL, Alonso A, Frutos MA. Differential analysis of donor characteristics for pancreas and islet transplantation. Transplant Proc. 2006; 38(8):2579-81.
  19. A L. Cuesta-Munoz, R. M. Briones, J. M. Mellado-Gil, J. M. Miranda, M. J. Castro, A. Navarro, S. Ruiz de Adana, A. Alonso, M. Gonzalez-Molina, B. Soria. Internal assessment of a novel islet isolation facility in Spain. Transplantation Proceedings 2005; 37(8):3404-6.
  20. Leda Pedelini, Maria Adelaida Garcia-Gimeno, Alberto Marina, Juan M. Gomez-Zumaquero, Pablo Rodriguez-Badía, Soledad López-Enriquez, Federico C. Soriguer, Antonio L. Cuesta-Muñoz and Pascual Sanz. Structure-function analysis of alpha5 and alpha13 helices of human glucokinase: description of two novel activating. Protein Science 2005;14(8):2080-6.
  21. Antonio Luis Cuesta Muñoz. Persistent Hyperinsulinemic Hypoglycemia. Encyclopedic Reference of Molecular Mechanisms of Disease. 2004. Editores: Springer-Verlag
  22. Antonio Luis Cuesta Muñoz. Defectos genéticos de la glucocinasa y alteraciones del metabolismo hidrocarbonado.Endocrinología y Nutrición, Monográfico. 2004
  23. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, Lopez-Enriquez S, Garcia-Gimeno MA, Sanz P, Soriguer FC, Laakso M. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes. 2004; 53(8):2164-8.
  24. A.L. Cuesta y Soria B.Transplante de islotes pancreáticos y obtención de células productoras de insulina a partir de células troncales. Cardivascular Risk Factors. 2004; 13(4): 237-242
  25. Soriguer F, Moreno F, Rojo-Martinez G, Garcia-Fuentes E, Tinahones F, Gomez-Zumaquero JM, Cuesta-Munoz AL, Cardona F, Morcillo S. Monounsaturated n-9 fatty acids and adipocyte lipolysis in rats. Br J Nutr. 2003;90(6):1015-22.
  26. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240-6.
  27. Soriguer-Escofet F, Esteva I, Rojo-Martinez G, Ruiz de Adana S, Catala M, Merelo MJ, Aguilar M, Tinahones F, Garcia-Almeida JM, Gomez-Zumaquero JM, Cuesta-Munoz AL, Ortego J, Freire JM; Diabets Group of the Andalusian Society of Endocrinology and Nutrtion. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002;56(3):213-20.
  28. Graeme I. Bell, Antonio Cuesta Muñoz and Franz M. Matschinsky.Glucokinase. En la “Wiley Encyclopedia of Molecular Medicine”; 2002: 1437-1440 Editorial: Ed. Thomas E. Creighton. John Wiley and Sons, Inc, New York.
  29. Pal R. Njolstd, Oddmund Sovik, Antonio Cuesta Muñoz, Lise B. Gundersen, Anders Molven, Dag Undlien, Mark A. Magnuson, Franz Matschinsky and Graeme I. Bell. Permanent neonatal diabetes mellitus due to complete glucokinase deficiency. New England Journal of Medicine, 2001; 344, Nº21: 1588-1592.
  30. Massa, F Meschi, A Cuesta-Muñoz, A Caumo, F Cerutti, S Toni, V Cherubini, L Guazzarotti, N Sulli, FM Matschinsky, R Lonini, D Iafusco, F Barbetti and the Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (SIEDP). High prevalence of glucokinase mutations in Italian children with MODY. Influence on Glucose Tolerance, Fisrt-Phase Insulin Response, Insulin Sensitivity and BMI. Diabetologia, 2001; 44: 898-905.
  31. Cuesta-Munoz A, Buettger C, Davis E, Shiota C, Magnuson MA, Grippo JF, Grimsby J, Matschinsky FM. Novel pharmacological glucokinase activators partly or fully reverse the catalytic defects of inactivating glucokinase missense mutations that cause MODY-2.  Diabetes 2001; 50:A109-110.
  32. Shah N, Zelent D, Najafi H, Burke C, Raper S, Cuesta-Munoz AL, Matschinsky FM, Jarett L. Electron microscopic demonstration of glucokinase in insulin granules of rat pancreatic beta cells. Diabetes 2001; 50: A353-A354.
  33. Franz M. Matschinsky, Antonio Cuesta-Muñoz, Elizabeth Davis, Carol Buettger, Ian Sweet, Michael Moates, and Mark A., Magnuson. The Glucokinase System and the Regulation of Blood Sugar. Frontiers in Diabetes Molecular  Pathogenesis of MODYs. Editores: Matschinsky FM, Magnuson MA. Clave: CL Año: 2000    Volumen 15  Páginas: Editorial: F. Belfiore. Karger. Basilea (Suiza)
  34. Weber IT, Harrison RW, Cuesta-Munoz A., Davis E, Matschinsky FMT. Molecular modeling of human glucokinase: Implications for the activity of mutants. Frontiers in Diabetes Molecular  Pathogenesis of MODYs. Nombre del editor en su caso: Matschinsky FM, Magnuson MA. Clave: CL    Año: 2000    Volumen:   Páginas: Editorial: F. Belfiore. Karger  (Suiza)
  35. E.A. Davis, A. Cuesta Muñoz, M. Raoul, C.W. Buettger, I. Sweet, M. Moates, M.A. Magnuson, F.M. Matschisky.Mutants of Glucokinase cause hypo and hyperglycemia Syndromes and their analisis iluminates fundamental quantitative concepts of glucose homeostasis. Diabetologia; 1999. 42:1175-1186.
  36. B. Mahalingam, A. Cuesta Muñoz, E.A. Davis, F.M. Matschisky, R.W. Harrison, Irene T Weber. Model in Human Glucokinase in complex with Glucose and ATP: Implications for mutants that cause hypo and hyperglycemia. Diabetes. 1999. 48:1698-1705.
  37. Glaser,B; Kesavan,P; Heyman,M; Davis, E; Cuesta, A; Buchs,A; Stanley,CA; Thornton,PS; Permutt,MA; Matschinsky,FM; Herold, KC. Familial hyperinsulinism caused by an activating glucokinase mutation. New England Journal of Medicine. 1998. 22; 338(4): 226-30.
  38. Kasavan, E.A. Davis, A. Cuesta Muñoz, I. Sweet, K. Niswender, Mark Magnuson and Franz Matschisky. Structural instability of mutant β-cell Glucokinase: implications for the molecular patogenesis of maturiry-onset diabetes of the young (type-2). Biochemical Journal. 1997; 322: 57-63.
  39. Cuesta Muñoz, Antonio, M. Revilla, L.F. Villa, E.R. Hernandez, H. Rico. Total and regional bone mineral content in Spanish professional ballet dancers. Calcified Tissue International. 1996; 58:150-154
  40. Soria, P., A. Cuesta, H. Romero, F.J. Martinez, A. Sastre. Dietary treatment of Limphoedema by restriction of long-chain triglycerides Angiology. 1994; 45:703- 707.
  41. Cuesta Muñoz, A.L., M. Revilla, A.Sastre Gallego. Calcio y composición corporal en los bailarines profesionales.Alimentación, Nutrición y Salud . 1994; 1:2-6.
  42. Cuesta Muñoz, A.L. Dietary intake and body composition in professional ballet dancers. International Journal of Sport Medicine. 1993; 14 (5):293-294
  43. Vidal Puig, A. Cuesta Muñoz, A.L., Hernaez Ugarte, I., A.Sastre Gallego. Principios generales para la correcta alimentación del paciente con diabetes mellitus. Nutrición Clínica. 1993; 13: 21-28.